Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SKN015
MIFTS: 66

Skin Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Skin Carcinoma

About this section

MalaCards integrated aliases for Skin Carcinoma:

Name: Skin Carcinoma 12 54 15 17
Skin Cancer 12 52 54 42 3 15
Melanoma and Non-Melanoma Skin Cancer 12
Malignant Neoplasm of Skin 12
Carcinoma of Skin 12
Ca - Skin Cancer 12
Cancer of Skin 12
Skin Cancers 15
Cancer, Skin 39

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3451 DOID:4159
MeSH 43 D012878
NCIt 49 C2920 C4914
SNOMED-CT 67 372130007
UMLS 71 C0007114 C0699893
Sources

Summaries for Skin Carcinoma

About this section
MedlinePlus : 42 Skin cancer is the most common form of cancer in the United States. The two most common types are basal cell cancer and squamous cell cancer. They usually form on the head, face, neck, hands, and arms. Another type of skin cancer, melanoma, is more dangerous but less common. Anyone can get skin cancer, but it is more common in people who Spend a lot of time in the sun or have been sunburned Have light-colored skin, hair and eyes Have a family member with skin cancer Are over age 50 You should have your doctor check any suspicious skin markings and any changes in the way your skin looks. Treatment is more likely to work well when cancer is found early. If not treated, some types of skin cancer cells can spread to other tissues and organs. Treatments include surgery, radiation therapy, chemotherapy, photodynamic therapy (PDT), and biologic therapy. PDT uses a drug and a type of laser light to kill cancer cells. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Skin Carcinoma, also known as skin cancer, is related to skin squamous cell carcinoma and xeroderma pigmentosum, complementation group f. An important gene associated with Skin Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Gastric cancer and Glioma. The drugs Isotretinoin and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and breast, and related phenotypes are Reduced mammosphere formation and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 An integumentary system cancer located in the skin that is the uncontrolled growth of abnormal skin cells.

CDC : 3 Skin cancer is the most common form of cancer in the United States. The two most common types of skin cancer-basal cell and squamous cell carcinomas-are highly curable, but can be disfiguring and costly to treat. Melanoma, the third most common skin cancer, is more dangerous and causes the most deaths. The majority of cases of these three types of skin cancer are caused by overexposure to ultraviolet (UV) light.

Sources

Related Diseases for Skin Carcinoma

About this section

Diseases in the Skin Carcinoma family:

Skin Carcinoma in Situ

Diseases related to Skin Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 756)
# Related Disease Score Top Affiliating Genes
1 skin squamous cell carcinoma 33.9 TP53 IVL CDH1
2 xeroderma pigmentosum, complementation group f 33.5 XPA ERCC6 ERCC2 DDB2
3 squamous cell carcinoma 33.2 TP53 TMC8 TMC6 PTGS2 PTCH1 IVL
4 xeroderma pigmentosum, complementation group c 33.2 XPA H2AC18 ERCC6 DDB2
5 basal cell nevus syndrome 33.2 XPA TP53 PTCH1 MC1R
6 epidermodysplasia verruciformis 1 33.1 TP53 TMC8 TMC6 CCR6
7 xeroderma pigmentosum, complementation group a 33.0 XPA TP53 H2AC18 ERCC6 ERCC2 DDB2
8 trichothiodystrophy 33.0 XPA ERCC6 ERCC2
9 xeroderma pigmentosum, complementation group d 32.8 XPA H2AC18 ERCC6 ERCC2 DDB2
10 basal cell carcinoma 32.8 XPA TYR TP53 PTGS2 PTCH1 MC1R
11 squamous cell carcinoma, head and neck 32.5 TP53 PTGS2 JUN ICOSLG H2AC18 ERCC6
12 xeroderma pigmentosum, complementation group g 32.5 XPA H2AC18 ERCC6 ERCC2 DDB2
13 uv-sensitive syndrome 32.5 XPA H2AC18 ERCC6 ERCC2 DDB2
14 vitiligo-associated multiple autoimmune disease susceptibility 1 31.3 TYR MC1R ICOSLG CCR6
15 inflammatory bowel disease 31.2 TP53 PTGS2 JUN ICOSLG CHGA CDH1
16 actinic keratosis 31.1 TYR TP53 TMC8 PTGS2 MC1R
17 cockayne syndrome 31.0 XPA TP53 ERCC6 ERCC2 DDB2
18 melanoma, cutaneous malignant 1 31.0 XPA TYR TP53 MC1R H2AC18 CDK4
19 nodular malignant melanoma 31.0 TYR TP53 MC1R CDK4
20 mutagen sensitivity 30.9 XPA TP53 ERCC2
21 anogenital venereal wart 30.8 TP53 H2AC18 CCR6
22 in situ carcinoma 30.8 TP53 H2AC18 CDH1
23 xeroderma pigmentosum, variant type 30.7 XPA TP53 PTCH1 POLH H2AC18 ERCC6
24 papilloma 30.7 TP53 PTGS2 JUN IVL CDH1 CCR6
25 li-fraumeni syndrome 30.6 TP53 PTCH1 DDB2 CDK4 CDH1
26 adenosquamous carcinoma 30.6 TP53 IVL CHGA
27 melanoma in congenital melanocytic nevus 30.6 TYR TP53 MC1R H2AC18 CDK4
28 keratosis, seborrheic 30.5 TP53 MC1R IVL
29 signet ring cell adenocarcinoma 30.5 TP53 CHGA CDH1
30 lung cancer 30.5 XPA TP53 PTGS2 JUN ICOSLG H2AC18
31 keratoacanthoma 30.5 TP53 IVL CDH1
32 skin disease 30.5 TYR TP53 MC1R IVL ICOSLG H2AC18
33 recessive dystrophic epidermolysis bullosa 30.5 TP53 JUN IVL
34 skin papilloma 30.5 TP53 PTGS2 JUN
35 adenoma 30.5 TP53 PTGS2 CHGA CDH1
36 muscle cancer 30.5 TP53 PTCH1 H2AC18 CDK4
37 oropharynx cancer 30.4 TP53 H2AC18 CDH1
38 oral cancer 30.4 TP53 PTGS2 CDH1
39 skin melanoma 30.4 TYR TP53 PTGS2 MC1R ICOSLG H2AC18
40 nasopharyngeal carcinoma 30.4 TP53 PTGS2 JUN CDK4 CDH1
41 pharynx cancer 30.4 TP53 H2AC18 CDH1 CCR6
42 neuroblastoma 30.4 TYR TP53 PTGS2 PTCH1 JUN CHGA
43 hutchinson-gilford progeria syndrome 30.4 XPA TP53 H2AC18 ERCC6
44 skin benign neoplasm 30.4 XPA PTCH1 JUN
45 cervical cancer 30.4 TP53 PTGS2 JUN CDK4 CDH1 CCR6
46 melanoma, uveal 30.4 TYR TP53 MC1R H2AC18 CDK4
47 exanthem 30.4 ICOSLG H2AC18 CCR6
48 suppression of tumorigenicity 12 30.4 TP53 PTGS2 H2AC18 CHGA CDK4 CDH1
49 peptic ulcer disease 30.4 TP53 PTGS2 H2AC18
50 fungal infectious disease 30.3 ICOSLG H2AC18 CCR6

Graphical network of the top 20 diseases related to Skin Carcinoma:



Diseases related to Skin Carcinoma
Sources

Symptoms & Phenotypes for Skin Carcinoma

About this section

GenomeRNAi Phenotypes related to Skin Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.5 CCR6 CDH1 CDK4 CHGA JUN POLH
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 DDB2 ERCC6 JUN
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 DDB2 ERCC6 JUN TP53
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.44 DDB2 ERCC2 ERCC6 JUN POLH TP53
5 Increased TP53 mRNA expression GR00389-S-5 8.85 JUN

MGI Mouse Phenotypes related to Skin Carcinoma:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.39 CDH1 CDK4 CHGA DDB2 ERCC2 ERCC6
2 cellular MP:0005384 10.33 CDH1 CDK4 DDB2 ERCC2 ERCC6 JUN
3 homeostasis/metabolism MP:0005376 10.27 CCR6 CDH1 CDK4 CHGA ERCC2 ERCC6
4 cardiovascular system MP:0005385 10.26 CCR6 CDH1 CDK4 CHGA JUN MC1R
5 immune system MP:0005387 10.25 CCR6 CDH1 CDK4 ERCC2 ERCC6 JUN
6 endocrine/exocrine gland MP:0005379 10.22 CDH1 CDK4 CHGA ERCC2 JUN PTCH1
7 hematopoietic system MP:0005397 10.22 CCR6 CDK4 ERCC2 ERCC6 JUN MC1R
8 integument MP:0010771 10.22 CDH1 CDK4 DDB2 ERCC2 ERCC6 JUN
9 neoplasm MP:0002006 10.15 CDH1 CDK4 DDB2 ERCC2 ERCC6 MC1R
10 craniofacial MP:0005382 10.08 CDK4 MC1R POLH PTCH1 TP53 TYR
11 nervous system MP:0003631 10.06 CCR6 CDK4 CHGA ERCC2 ERCC6 JUN
12 hearing/vestibular/ear MP:0005377 9.97 ERCC6 MC1R POLH PTCH1 TP53 TYR
13 no phenotypic analysis MP:0003012 9.86 CDH1 CHGA JUN MC1R PTCH1 PTGS2
14 pigmentation MP:0001186 9.76 CDK4 ERCC2 MC1R POLH PTCH1 TP53
15 skeleton MP:0005390 9.65 CDK4 ERCC2 ERCC6 JUN PTCH1 PTGS2
16 vision/eye MP:0005391 9.28 CDK4 ERCC2 ERCC6 JUN PTCH1 PTGS2
Sources

Drugs & Therapeutics for Skin Carcinoma

About this section

Drugs for Skin Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 381)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
4
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
5
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
6
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
7
Ethanol Approved Phase 4 64-17-5 702
8
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
11
Citalopram Approved Phase 4 59729-33-8 2771
12
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
13
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
14
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
15
Fluorouracil Approved Phase 4 51-21-8 3385
16
Menthol Approved Phase 4 2216-51-5 16666
17
Adalimumab Approved Phase 4 331731-18-1 16219006
18
Tofacitinib Approved, Investigational Phase 4 477600-75-2
19
Etanercept Approved, Investigational Phase 4 185243-69-0
20
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
21
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
22
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
23
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
24
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
25
Aminolevulinic acid Approved Phase 4 106-60-5 137
26
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
27
Vemurafenib Approved Phase 4 918504-65-1 23252090 42611257
28
Mycophenolic acid Approved Phase 4 24280-93-1 446541
29
Azathioprine Approved Phase 4 446-86-6 2265
30
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
31
Aldesleukin Approved Phase 4 85898-30-2, 110942-02-4
32
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
33
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
34
Testosterone enanthate Approved Phase 4 315-37-7 9416
35
Methyltestosterone Approved Phase 4 58-18-4 6010
36
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
37
Epicatechin Investigational Phase 4 490-46-0, 35323-91-2 72276
38
Theobromine Investigational Phase 4 83-67-0 5429
39 Cyclooxygenase Inhibitors Phase 4
40 Gastrointestinal Agents Phase 4
41 Laxatives Phase 4
42 Cathartics Phase 4
43 Carboxymethylcellulose Sodium Phase 4
44 Salicylates Phase 4
45 Anti-Inflammatory Agents Phase 4
46 Anti-Inflammatory Agents, Non-Steroidal Phase 4
47 Tin Fluorides Phase 4
48 triamcinolone acetonide Phase 4
49 Triamcinolone diacetate Phase 4
50 Triamcinolone hexacetonide Phase 4

Interventional clinical trials:

(show top 50) (show all 722)
# Name Status NCT ID Phase Drugs
1 Treatment of Superficial Basal Cell Carcinoma by Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Topical Photodynamic Therapy With Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® Unknown status NCT01553032 Phase 4 Erbitux®
3 Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study Unknown status NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
4 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
5 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
6 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
7 The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound Unknown status NCT00813631 Phase 4
8 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
9 Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
10 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
11 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
12 Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients Completed NCT00492895 Phase 4 Discontinuation of Azathioprin
13 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
14 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
15 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
16 A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial Completed NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
17 3% Dihydroxyacetone (DHA or Sunless Tanning Agent) Inhibits Vitamin D Production in the Skin in Response to Ultraviolet Light Completed NCT00818467 Phase 4
18 Phase 4 Study of Paricalcitol and Calcitriol for Reparative Management of Chronic Allograft Dysfunction and Renocardiac Syndrome in Vitamin D Insufficient Renal Transplant Recipients Completed NCT01265615 Phase 4 Paricalcitol;Calcitriol;Cholecalciferol
19 A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
20 A Randomized, Double-Blinded Study of Epiceram Versus Elidel in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)
21 IL-2 Neuropsychiatric Symptoms: Mechanism and Prevention Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
22 A Randomized Open Label Study to Evaluate the Safety and Efficacy if Imiquimod 5% Cream Applied 3 Times Per Week for 8 or 12 Weeks in the Treatment of Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
23 Can Vitamin D Supplementation Prevent Type 2 Diabetes by Improving Insulin Sensitivity and Secretion in Overweight Humans? Completed NCT02112721 Phase 4
24 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
25 A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses Recruiting NCT03963102 Phase 4 Ameluz
26 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
27 Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease: a Multicenter Randomized Controlled Trial Recruiting NCT03909646 Phase 4 Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram;5Fluorouracil
28 PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS Active, not recruiting NCT02092467 Phase 4 tofacitinib;tofacitinib
29 COcoa Supplement and Multivitamin Outcomes Study Active, not recruiting NCT02422745 Phase 4
30 Randomized Trial of Bupivacaine as Adjuvant for Post-operative Pain in Mohs Micrographic Surgery Not yet recruiting NCT04362566 Phase 4 Bupivacaine
31 A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer Terminated NCT01459666 Phase 4 Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
32 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
33 An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
34 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
35 Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
36 Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
37 A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
38 The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes: OTEST Terminated NCT01510847 Phase 4 Andriol Testocaps
39 CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial Unknown status NCT00799188 Phase 3 Everolimus
40 A Randomized Clinical Trial in the Surgical Treatment of Basal Cell Carcinoma of the Eyelid: Surgical Excision With Frozen Section vs. Permanent Section Control Unknown status NCT00663650 Phase 3
41 A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
42 Continuative vs Sequential Phototherapy in Non-segmental Vitiligo Patients Unknown status NCT00525395 Phase 3
43 Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors Completed NCT00133887 Phase 3 rapamycin;ciclosporine;tacrolimus
44 Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers Completed NCT03131713 Phase 3 Acetaminophen
45 Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial Completed NCT00005884 Phase 3 eflornithine
46 A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody
47 A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma Completed NCT01763164 Phase 3 MEK162;Dacarbazine
48 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
49 CSP #402 - VA Topical Tretinoin Chemoprevention Trial Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
50 Evaluation of Pigmented Skin Lesions With MelaFind(R) System Completed NCT00434057 Phase 3

Search NIH Clinical Center for Skin Carcinoma

Sources

Genetic Tests for Skin Carcinoma

About this section
Sources

Anatomical Context for Skin Carcinoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Skin Carcinoma:

19
Skin

MalaCards organs/tissues related to Skin Carcinoma:

40
Skin, Prostate, Breast, Kidney, Lung, T Cells, Liver
Sources

Publications for Skin Carcinoma

About this section

Articles related to Skin Carcinoma:

(show top 50) (show all 18574)
# Title Authors PMID Year
1
Artificial Intelligence-Based Skin Cancer Phone Apps Unreliable. 61 42
32286633 2020
2
When to suspect a non-melanoma skin cancer. 42 61
32161002 2020
3
Time to address disparities in the standard of care for Kaposi sarcoma. 42
32145826 2020
4
Signaling pathways in melanosome biogenesis and pathology. 61 54
20381640 2010
5
TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes. 54 61
20399617 2010
6
Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1. 61 54
20096264 2010
7
Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients. 54 61
19818066 2010
8
Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma. 61 54
20129839 2010
9
The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans. 61 54
20126537 2010
10
Predictive testing of the melanocortin 1 receptor for skin cancer and photoaging. 61 54
20066389 2010
11
MMP-10 (Stromelysin-2) and MMP-21 in human and murine squamous cell cancer. 61 54
19601983 2009
12
Aberrant trafficking of human melanocortin 1 receptor variants associated with red hair and skin cancer: Steady-state retention of mutant forms in the proximal golgi. 61 54
19452503 2009
13
Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. 61 54
19445931 2009
14
The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. 54 61
19667145 2009
15
Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. 54 61
19384953 2009
16
Aberrant cytokeratin expression during arsenic-induced acquired malignant phenotype in human HaCaT keratinocytes consistent with epidermal carcinogenesis. 61 54
19524636 2009
17
DNA polymerase zeta cooperates with polymerases kappa and iota in translesion DNA synthesis across pyrimidine photodimers in cells from XPV patients. 54 61
19564618 2009
18
Identification and functional analysis of novel variants of the human melanocortin 1 receptor found in melanoma patients. 54 61
19338054 2009
19
Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients. 54 61
19320745 2009
20
p53 protein expression in skin with different levels of photoaging. 54 61
19292788 2009
21
c-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer. 54 61
19204086 2009
22
Vitamin D and skin cancer: a meta-analysis. 54 61
19008093 2009
23
Differential activity of UV-DDB in mouse keratinocytes and fibroblasts: impact on DNA repair and UV-induced skin cancer. 61 54
18996499 2009
24
Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval. 54 61
19096907 2009
25
The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A>G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population. 54 61
18637131 2009
26
Comparative study of nucleotide excision repair defects between XPD-mutated fibroblasts derived from trichothiodystrophy and xeroderma pigmentosum patients. 54 61
18817897 2008
27
Identification of the minimal melanocyte-specific promoter in the melanocortin receptor 1 gene. 54 61
19017395 2008
28
Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism. 61 54
18787544 2008
29
A novel AKT3 mutation in melanoma tumours and cell lines. 61 54
18813315 2008
30
Persistence of repair proteins at unrepaired DNA damage distinguishes diseases with ERCC2 (XPD) mutations: cancer-prone xeroderma pigmentosum vs. non-cancer-prone trichothiodystrophy. 61 54
18470933 2008
31
Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients. 54 61
18469853 2008
32
Polymorphisms of the VDR gene are associated with presence of solar keratoses on the skin. 54 61
18647306 2008
33
Prenatal manifestation in a family affected by nevoid basal cell carcinoma syndrome. 61 54
18539553 2008
34
Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. 61 54
18510673 2008
35
FLIP ing the coin? Death receptor-mediated signals during skin tumorigenesis. 61 54
18558995 2008
36
Degradation of HPV20E6 by p53: Delta Np63 alpha and mutant p53R248W protect the wild type p53 mediated caspase-degradation. 61 54
18412244 2008
37
p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. 54 61
18219279 2008
38
Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells. 54 61
18292087 2008
39
Melanocytes expressing MC1R polymorphisms associated with red hair color have altered MSH-ligand activated pigmentary responses in coculture with keratinocytes. 54 61
17960564 2008
40
Comparison of induced and cancer-associated mutational spectra using multivariate data analysis. 54 61
18296683 2008
41
Nucleotide diversity and population differentiation of the melanocortin 1 receptor gene, MC1R. 61 54
18402696 2008
42
Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. 54 61
18191509 2008
43
The melanocortin 1 receptor and the UV response of human melanocytes--a shift in paradigm. 54 61
18282187 2008
44
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). 54 61
17939062 2008
45
Targeting mutant p53 shows promise for sunscreens and skin cancer. 54 61
18060027 2007
46
CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. 54 61
18060030 2007
47
Melanocortin 1 receptor (MC1R) genotype influences erythemal sensitivity to psoralen-ultraviolet A photochemotherapy. 54 61
17916200 2007
48
p53 and the pathogenesis of skin cancer. 54 61
17270229 2007
49
Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. 54 61
17988327 2007
50
Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. 54 61
17616515 2007
Sources

Variations for Skin Carcinoma

About this section

Cosmic variations for Skin Carcinoma:

9 (show top 50) (show all 2121)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM152022165 YES1 skin,eye,carcinoma,squamous cell carcinoma c.851G>A p.G284E 18:743289-743289 52
2 COSM85720102 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2065C>T p.R689C 9:132903794-132903794 52
3 COSM90145852 TRAF7 skin,eye,carcinoma,squamous cell carcinoma c.349G>A p.E117K 16:2171264-2171264 52
4 COSM87910628 TP53 skin,face,carcinoma,squamous cell carcinoma c.772G>A p.E258K 17:7674191-7674191 52
5 COSM87910495 TP53 skin,face,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 52
6 COSM87899076 TP53 skin,hand,carcinoma,squamous cell carcinoma c.673-1G>A p.? 17:7674291-7674291 52
7 COSM87899887 TP53 skin,hand,carcinoma,squamous cell carcinoma c.856G>A p.E286K 17:7673764-7673764 52
8 COSM88003733 TP53 skin,arm,carcinoma,squamous cell carcinoma c.1096T>G p.S366A 17:7670613-7670613 52
9 COSM87905569 TP53 skin,face,carcinoma,squamous cell carcinoma c.740A>C p.N247T 17:7674223-7674223 52
10 COSM87906137 TP53 skin,hand,carcinoma,squamous cell carcinoma c.260C>A p.P87Q 17:7676109-7676109 52
11 COSM87899145 TP53 skin,face,carcinoma,squamous cell carcinoma c.763A>T p.I255F 17:7674200-7674200 52
12 COSM87915681 TP53 skin,hand,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 17:7676059-7676059 52
13 COSM87899377 TP53 skin,face,carcinoma,squamous cell carcinoma c.375+1G>A p.? 17:7675993-7675993 52
14 COSM87906799 TP53 skin,eye,carcinoma,squamous cell carcinoma c.839G>C p.R280T 17:7673781-7673781 52
15 COSM88075392 TP53 skin,hand,carcinoma,squamous cell carcinoma c.950A>G p.Q317R 17:7673578-7673578 52
16 COSM87897711 TP53 skin,hand,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 52
17 COSM87897627 TP53 skin,face,carcinoma,squamous cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 52
18 COSM87917387 TP53 skin,face,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 52
19 COSM87955907 TP53 skin,hand,carcinoma,squamous cell carcinoma c.845G>C p.R282P 17:7673775-7673775 52
20 COSM87970671 TP53 skin,face,carcinoma,squamous cell carcinoma c.766A>C p.T256P 17:7674197-7674197 52
21 COSM87906379 TP53 skin,hand,carcinoma,squamous cell carcinoma c.647T>A p.V216E 17:7674884-7674884 52
22 COSM87933373 TP53 skin,arm,carcinoma,squamous cell carcinoma c.859G>A p.E287K 17:7673761-7673761 52
23 COSM87898836 TP53 skin,hand,carcinoma,squamous cell carcinoma c.560-1G>A p.? 17:7674972-7674972 52
24 COSM87991360 TP53 skin,face,carcinoma,squamous cell carcinoma c.714T>A p.C238* 17:7674249-7674249 52
25 COSM87952409 TP53 skin,eye,carcinoma,squamous cell carcinoma c.859G>C p.E287Q 17:7673761-7673761 52
26 COSM88003756 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>C p.A189P 17:7674966-7674966 52
27 COSM88016543 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>A p.A189T 17:7674966-7674966 52
28 COSM87961289 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 52
29 COSM88117113 TP53 skin,hand,carcinoma,squamous cell carcinoma c.590T>C p.V197A 17:7674941-7674941 52
30 COSM87898351 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 52
31 COSM87901804 TP53 skin,eye,carcinoma,squamous cell carcinoma c.587G>T p.R196L 17:7674944-7674944 52
32 COSM87898463 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 52
33 COSM135128838 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1259C>T p.S420F 9:99146601-99146601 52
34 COSM96398090 STK40 skin,eye,carcinoma,squamous cell carcinoma c.1280C>T p.S427F 1:36341798-36341798 52
35 COSM99818572 SPEN skin,eye,carcinoma,squamous cell carcinoma c.9563C>T p.P3188L 1:15935803-15935803 52
36 COSM89675474 SOX2 skin,eye,carcinoma,squamous cell carcinoma c.237G>A p.W79* 3:181712597-181712597 52
37 COSM84678061 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 52
38 COSM140185011 RNF43 skin,eye,carcinoma,squamous cell carcinoma c.866C>T p.S289F 17:58360235-58360235 52
39 COSM86828717 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 52
40 COSM94496882 RAD52 skin,eye,carcinoma,squamous cell carcinoma c.779G>A p.R260Q 12:916430-916430 52
41 COSM94496058 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 52
42 COSM97061657 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 52
43 COSM97061670 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 52
44 COSM101904169 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 52
45 COSM101917565 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 52
46 COSM101909541 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 52
47 COSM90829299 PTCH1 skin,face,carcinoma,squamous cell carcinoma c.3724G>A p.E1242K 9:95449149-95449149 52
48 COSM112619412 PPP6C skin,eye,carcinoma,squamous cell carcinoma c.901C>T p.R301C 9:125149801-125149801 52
49 COSM135344063 PLCG2 skin,neck,carcinoma,squamous cell carcinoma c.115G>T p.E39* 16:81786104-81786104 52
50 COSM125322720 PIK3R1 skin,eye,carcinoma,squamous cell carcinoma c.608A>G p.Y203C 5:68279707-68279707 52
Sources

Expression for Skin Carcinoma

About this section
Search GEO for disease gene expression data for Skin Carcinoma.
Sources

Pathways for Skin Carcinoma

About this section

Pathways related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Gastric cancer 36
Show member pathways
 12.59 TP53 JUN DDB2 CDK4 CDH1
2
Glioma 36
Show member pathways
 12.51 TP53 JUN DDB2 CDK4 CDH1
3
Pathways in cancer 36
12.42 TP53 PTGS2 PTCH1 JUN DDB2 CDK4
4
Chks in Checkpoint Regulation 63
Show member pathways
 12.41 XPA TP53 POLH ERCC6 ERCC2 CDK4
5
WNT Signaling 63
12.2 TP53 PTGS2 JUN CDK4 CDH1
6
Integrated Breast Cancer Pathway 1
11.95 TP53 JUN CDK4 CDH1
7
DNA Damage 4
11.9 XPA TP53 POLH ERCC2 DDB2 CDK4
8
Nucleotide excision repair 36
Show member pathways
 11.73 XPA ERCC6 ERCC2 DDB2
9
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.61 PTGS2 JUN CDK4
10
Platinum drug resistance 36
11.59 XPA TP53 POLH
11
Bladder cancer 36 1
11.58 TP53 CDK4 CDH1
12
Transcription_P53 signaling pathway 22
11.53 XPA TP53 JUN ERCC2
13
Small cell lung cancer 36
11.52 TP53 PTGS2 DDB2 CDK4
14
Hepatitis C and Hepatocellular Carcinoma 1
11.36 TP53 PTGS2 JUN
15
Signaling mediated by p38-alpha and p38-beta 1
11.15 TP53 PTGS2 JUN
16
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 60
10.39 XPA POLH ERCC6 ERCC2
Sources

GO Terms for Skin Carcinoma

About this section

Cellular components related to Skin Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear membrane GO:0031965 8.92 TP53 TMC8 TMC6 CDK4

Biological processes related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 10.04 XPA TP53 POLH ERCC6 ERCC2 DDB2
2 DNA repair GO:0006281 10 XPA POLH ERCC6 ERCC2 DDB2
3 regulation of cell proliferation GO:0042127 9.88 TP53 PTGS2 PTCH1 JUN CDK4
4 response to drug GO:0042493 9.85 TP53 PTGS2 PTCH1 JUN CDK4 CDH1
5 response to toxic substance GO:0009636 9.84 XPA ERCC6 CDK4 CDH1
6 response to organic substance GO:0010033 9.81 PTGS2 JUN CDK4 CDH1
7 transcription-coupled nucleotide-excision repair GO:0006283 9.8 XPA ERCC6 ERCC2
8 embryonic organ development GO:0048568 9.77 TP53 PTCH1 ERCC2
9 nucleotide-excision repair, DNA incision GO:0033683 9.77 XPA ERCC2 DDB2
10 response to radiation GO:0009314 9.76 PTGS2 POLH JUN
11 multicellular organism growth GO:0035264 9.76 XPA TP53 ERCC6 ERCC2
12 nucleotide-excision repair, DNA incision, 5'-to lesion GO:0006296 9.75 XPA ERCC2 DDB2
13 nucleotide-excision repair, preincision complex assembly GO:0006294 9.73 XPA ERCC2 DDB2
14 global genome nucleotide-excision repair GO:0070911 9.72 XPA ERCC2 DDB2
15 nucleotide-excision repair, DNA incision, 3'-to lesion GO:0006295 9.7 XPA ERCC2 DDB2
16 nucleotide-excision repair, DNA duplex unwinding GO:0000717 9.67 XPA ERCC2 DDB2
17 melanin biosynthetic process GO:0042438 9.63 TYR MC1R
18 negative regulation of blood vessel diameter GO:0097756 9.63 PTGS2 CHGA
19 response to UV-B GO:0010224 9.62 IVL ERCC6
20 cellular response to UV-C GO:0071494 9.61 TP53 POLH
21 nucleotide-excision repair, preincision complex stabilization GO:0006293 9.61 XPA ERCC2 DDB2
22 UV protection GO:0009650 9.58 XPA MC1R ERCC2
23 nucleotide-excision repair GO:0006289 9.56 XPA TP53 ERCC2 DDB2
24 response to oxidative stress GO:0006979 9.55 XPA TP53 PTGS2 ERCC6 ERCC2
25 UV-damage excision repair GO:0070914 9.5 XPA MC1R DDB2
26 pyrimidine dimer repair GO:0006290 9.13 POLH ERCC6 DDB2
27 response to UV GO:0009411 9.1 XPA TYR TP53 ERCC6 ERCC2 DDB2

Molecular functions related to Skin Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 XPA TYR TP53 TMC8 TMC6 PTGS2
2 protein-containing complex binding GO:0044877 9.35 PTCH1 JUN ERCC6 DDB2 CDK4
3 mechanosensitive ion channel activity GO:0008381 9.26 TMC8 TMC6
4 damaged DNA binding GO:0003684 8.92 XPA POLH ERCC2 DDB2
Sources

Sources for Skin Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....